Day: April 17, 2020

ARLINGTON, Va. and LONDON, April 17, 2020 (GLOBE NEWSWIRE) — Willis Towers Watson (NASDAQ: WLTW), a leading global advisory, broking and solutions company, will announce its financial results for the first quarter 2020 on Thursday April 30, 2020.The company will host a conference call to discuss its financial results at 9:30 a.m. Eastern Time on April 30, 2020. A live broadcast of the conference call will be available online at the Investor Relations section of www.willistowerswatson.com. The time has been updated from the earlier announcement, which was made on April 13, 2020.An online replay at www.willistowerswatson.com will be available shortly after the call.  A telephonic replay of the call will also be available for 24 hours at 404-537-3406, conference ID 5575899.ABOUT WILLIS TOWERS WATSONWillis Towers Watson (NASDAQ: WLTW)...

MADRID, Spain and CAMBRIDGE, Mass., April 17, 2020 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces today that, since the emergence of the COVID-19 pandemic, the company has been implementing and executing contingency plans necessary to ensure the health and safety of its employees, partners and clinical trial participants. These plans have been formulated to enable business continuity, and allow the company to fulfill its responsibility to continue developing experimental drugs for serious illnesses with unmet medical needs.Oryzon has implemented a set of measures aligned with these principles and has carefully followed the recommendations enacted by the authorities....

MADRID, Spain and CAMBRIDGE, Mass., April 17, 2020 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with high unmet medical need, is pleased to announce the appointment of Dr. Vanessa Almendro Navarro, of Eisai US, as an independent director. Dr. Almendro will be Lead Director and member of the Remuneration and Nomination Committee.Carlos Buesa, CEO of Oryzon, said: “We welcome Vanessa to our board. As an oncologist with extensive experience in drug development, she is a recognized expert in the US biotech industry. We very much look forward to her guidance and support as we execute on our objectives in the coming years.”Dr. Almendro has extensive experience in corporate strategy, and in the clinical...

PITTSBURGH, April 17, 2020 (GLOBE NEWSWIRE) — United States Steel Corporation (NYSE: X) announced today that interested stockholders, investors and others may listen to the company’s first quarter 2020 conference call with securities analysts on May 1, at 8:30 a.m. EDT.  The call, which will be available via the U. S. Steel website, will cover first quarter financial results and may include forward-looking information.  The company plans to release its first quarter financial results following the close of trading on the New York Stock Exchange on Thursday, April 30, 2020.U. S. Steel officials participating in the call will be; David B. Burritt, President and Chief Executive Officer, Christine S. Breves, Senior Vice President and Chief Financial Officer, Rich Fruehauf, Senior Vice President, Chief Strategy and Development Officer,...

Cash position of €5.7 million at December 31, 2019, combined with $6.6 million from new agreement with Acrotech, provide extended financial visibility into Q2 2021AsiDNA™ to advance to phase 1b/2 study REVOCAN in combination with niraparib in patients with relapsed ovarian cancer to evaluate effect on acquired resistance with preliminary data possibly by end 2020/early 2021Topline results from DRIIV-1b study of AsiDNA™ in combination with reference chemotherapy in multi-treated advanced solid tumors expected by end 2020Impact of Covid-19 on Company’s operations are limited, assuming the situation improves in Q3 2020PARIS, April 17, 2020 (GLOBE NEWSWIRE) — Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, “the Company” or “the Group”), a clinical-stage biotechnology company specializing in the...

Publicité des honoraires des commissaires aux comptes(pour la Caisse Régionale d’Ile-de-France et ses filiales consolidées) (1)  Y compris les prestations d’experts indépendants ou du réseau à la demande des commissaires aux comptes dans le cadre de la certification des comptes.Retrouvez toutes les informations financières réglementaires sur ca-paris.com, rubrique “Finance / Informations Financières” (accès gratuit et illimité pour les particuliers, hors coût de communication variable selon l’opérateur).Contact : communicationfinanciere-caidf@ca-paris.frPièce jointeCA IDF Honoraires des Commissaires aux Comptes 2019

WILLIAMSVILLE, NY, April 17, 2020 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant biotechnology company focused on reduced nicotine content tobacco and hemp/cannabis plant genetics research and development, announced today that the U.S. Food and Drug Administration (FDA) has set May 18, 2020 as the deadline for the submission of public comments on the Company’s Modified Risk Tobacco Product (MRTP) Application.22nd Century’s MRTP application seeks authorization from the FDA to allow the Company to market its reduced nicotine content cigarettes under the brand name VLN®, with pack and advertising claims stating that the product contains 95% less nicotine than conventional tobacco cigarettes, as well as related claims regarding reduced nicotine exposure.   “We are very...

April 17th, 2020RCI BANQUE: 2nd SUPPLEMENT TO EMTN PROGRAMME BASE PROSPECTUSThe second Supplement (dated 16th April 2019) to RCI Banque EMTN Programme Base Prospectus, dated September 5th, 2019, is available on the Autorité des Marchés Financiers web site (www.amf-france.org) and on RCI Banque web site (www.rcibs.com).AttachmentRCI Banque – Supplement 2 to 2019 Base Prospectus 253626-4-23742 v0.1

Le 17 avril 2020RCI BANQUE : 2nd SUPPLEMENT AU PROSPECTUS DE BASE DU PROGRAMME EMTNLe deuxième Supplément (daté du 16 avril 2020) au Prospectus de Base du Programme EMTN de RCI Banque, daté du 5 septembre 2019, est disponible sur le site de l’Autorité des Marchés Financiers (www.amf-france.org) ainsi que sur le site de RCI Banque (www.rcibs.com).Pièce jointeRCI Banque – Supplement 2 to 2019 Base Prospectus 253626-4-23742 v0.1